Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of chronic heart failure cases, and effective therapies have been limited. This course reviews the EMPEROR-PRESERVED Trial and discusses whether or not the use of empagliflozin on heart failure in patients with HFpEF provides positive outcomes.

Upon successful completion of this application-based course, participants should be able to:
1. Summarize current heart failure management strategies and guidelines
2. Describe the use of SGLT2i’s in heart failure management
3. Interpret the results of the EMPEROR-PRESERVED Trial
4. Discuss the validity of the EMPEROR-PRESERVED Trial
5. Apply the EMPEROR-PRESERVED Trial results to a patient case

Troy Lynn Lewis, Pharm.D., BC-ADM
Assistant Professor of Pharmacy Practice
Wilkes University

Troy Lynn Lewis has no relevant financial relationships to disclose.

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below and attend the live webinar.

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Membership. To get more courses like this sent to you every month, sign-up!

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: September 14, 2022
Planned Expiration Date: September 14, 2025 

Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.